High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma

References

• Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States,1985–1999. Neuro Oncol 2006;8:27–37.
   PubMed Web of Science ®Google Scholar
• Haldorsen IS, Krossnes BK, Aarseth JH, et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003:time trends in a 15-year national survey. Cancer 2007;110:1804–1814.
   Web of Science ®Google Scholar
• Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma. Cancer 2002;95:1504–1510.
   PubMed Web of Science ®Google Scholar
• Kadan-Lottick NS, Skluzarek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193–202.
   PubMed Web of Science ®Google Scholar
• Mead GM, Bleehen NM, Gregor A, et al. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359–1370.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407–2414.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188–195.
   PubMed Web of Science ®Google Scholar
• Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259–268.
   PubMed Web of Science ®Google Scholar
• DeAngelis L, Seiferheld W, Schold C, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Onoclogy Group Study 93–10. J Clin Oncol 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr D, de Graaf SSN. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing. Cancer 2002;94:1815–1820.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005;26:258–265.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859–863.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 2003;21:1044–1049.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24: 4570–4574.
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 1996;46:1757–1759.
   PubMed Web of Science ®Google Scholar
• Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000–3006.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot of the BOMES protocol. Cancer 1998;82:1946–1951.
   PubMed Web of Science ®Google Scholar
• Khan RB, Weije S, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? . J Neurooncol 2002;58:175–178.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC, Cairncross JC. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–1280.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yaholm J. Primary central nervous system lymphoma.In: DeVita V, editor. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp 2330–2332.
   Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994;81:188–195.
   PubMed Web of Science ®Google Scholar
• Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000;46:19–26.
   PubMed Web of Science ®Google Scholar
• Boiardi A, Silvani A, Valentini S, Salmaggi A, Allegranza A, Broggi G. Chemotherapy as first treatment for primary malignant non-Hodgkin’s lymphoma of the central nervous system preliminary data. J Neurol 1993;241:96–100.
   PubMed Web of Science ®Google Scholar
• Blay JY, Couhour D, Carrie C, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin’s lymphoma of patients with no known cause of immunosuppression. Blood 1995;86 2922–2929.
   PubMed Web of Science ®Google Scholar
• Bessell EM, Graus F, Punt JA, Firth J. Primary non-Hodgkin’s lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996;14:945–954.
   PubMed Web of Science ®Google Scholar
• Glass J, Shusik C, Hochberg FH, Cher L, Gruber M. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996;30:257–265.
   PubMed Web of Science ®Google Scholar
• Dent S, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart D. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J Neurooncol 1996;28:25–30.
   PubMed Web of Science ®Google Scholar
• Korfel A, Thiel E. Successful treatment of non-Hodgkin’s lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leuk Lymphoma 1998;30:609–617.
   PubMed Web of Science ®Google Scholar
• Brada M, Hjiyiannakis D, Hines F, Tralsh D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998;40:1157–1162.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial. Lancet 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51:247–252.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kuker Wk, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843–847.
   PubMed Web of Science ®Google Scholar
• Ferreri A, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21: 266–272.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711–5715.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomized, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
   PubMed Web of Science ®Google Scholar
• Gavrillovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Neurooncol 2006;58:175–178.
   Google Scholar
• Shah G, Yahalom J, Correa DD, Lai RK, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730–4735.
   PubMed Web of Science ®Google Scholar